Entrada positive Phase 1/2 Duchenne data, non-GAAP EPS $-0.95 beats, revenue misses

 

Entrada posts positive Phase 1/2 ENTR-601-44 Duchenne data and Q1 2026 non-GAAP EPS $-0.95 beats, revenue $875,000 misses estimates

• Phase 1/2 ENTR-601-44 Duchenne study showed functional gains, increased dystrophin expression and a favorable safety profile in treated patients.
• Cohort 1 of ELEVATE-44-201 showed statistically significant improvement on the Time to Rise functional measure.
• Company has begun dosing a higher-dose Cohort 2 of ELEVATE-44-201, with data expected by year-end 2026.
• Q1 2026 non-GAAP EPS was $-0.95, down 126% YoY from the prior year.
• Q1 2026 revenue of $875,000 declined 96% YoY versus the prior year period.
• Q1 2026 net loss widened to $39.7 million on $0.9 million in collaboration revenue.
• Company ended Q1 2026 with $255 million in cash and investments.
• Entrada expects existing cash and investments to fund operations into the third quarter of 2027.

https://finviz.com/quote?t=TRDA&p=d